Keywords: Canada, EU trade agreement, CETA, CGPA, Rx&D, Intellectual property

Canada would lose out on generic industry investment by adopting EU pharma proposals, warns CGPA

Article | 12 October 2011

Canada could face a loss of jobs and investment in its R&D intensive and fast-growing generic pharmaceutical industry ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in